ArunA Biomedical Inc. is dedicated to advancing drug discovery and basic research through development and commercialization of products and services derived from or related to human stem cells.

“Embryonic stem cells, the master cells of human life, have the potential to differentiate into all cell types found in humans. Someday stem cells will be used therapeutically. Today these cells allow us to find more efficient ways to identify new drugs and test them for potential side effects earlier in the drug development process.  Finding failures earlier in the drug discovery and development process will save money and bring drugs more quickly to market. The potential impact of our products in the drug discovery and research communities could be astounding." says ArunA co-founder and Chairman Steven Stice.

New Research Tools for Drug Discovery
With our proprietary technology, ArunA creates reliable, robust and highly scalable human stem cell systems.  These new and innovative research tools reduce both time and effort and are uniquely suitable for a wide range of applications and assays, e.g., cellular model studies, high content screening, developmental studies, RNAi studies and genetic manipulation. ArunA’s adherent monolayer technology, eliminates most of the difficulties encountered in studies using other sources of stem cells and their derivatives.  The adherent monolayer can readily be used in standard assay formats, from 96-well plates to flasks.  Also for drug screening and toxicity studies, all cells in the assay are uniformly exposed to the test agent ensuring the quality of assay results.  ArunA’s serum-free and feeder-free adherent monolayer technology platform provides “off the shelf” access to normal human cell types.

Because they are derived from human embryonic stem cells using proprietary technology, ArunA’s human cells are robust, easily maintained, highly proliferative, and readily grown into large populations needed for today’s high throughput research. Large numbers of cells can be produced in less than 10 passages, thus avoiding the pitfalls of using other embryonic stem cell sources and technology.